EBV-encoded small RNA1 and nonresolving inflammation in rheumatoid arthritis  by Chiu, Wen-Chan et al.
Kaohsiung Journal of Medical Sciences (2013) 29, 606e610Available online at www.sciencedirect.com
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLEEBV-encoded small RNA1 and nonresolving
inflammation in rheumatoid arthritisWen-Chan Chiu a, Ching-Mei Chen b, Tien-Tsai Cheng a, Huey-Ling You b,
Shan-Fu Yu a, Lin-Hsiu Weng c, Hsuan-Ying Huang d, Chao-Cheng Huang d,
Chung-Jen Chen a,*aDivision of Rheumatology, Allergy, and Immunology, Department of Internal Medicine,
Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine,
Kaohsiung, Taiwan
bDepartment of Laboratory Medicine, Kaohsiung Chang Gung Memorial Hospital and
Chang Gung University College of Medicine, Kaohsiung, Taiwan
cDepartment of Orthopedics, Kaohsiung Chang Gung Memorial Hospital and
Chang Gung University College of Medicine, Kaohsiung, Taiwan
dDepartment of Anatomic Pathology, Kaohsiung Chang Gung Memorial Hospital and
Chang Gung University College of Medicine, Kaohsiung, TaiwanReceived 30 July 2012; accepted 1 October 2012
Available online 13 August 2013KEYWORDS
EBER1;
Inflammation;
Rheumatoid arthritis* Corresponding author. Division of
Memorial Hospital and Chang Gung Un
E-mail address: chungjen@adm.cg
1607-551X/$36 Copyright ª 2013, Kao
http://dx.doi.org/10.1016/j.kjms.201Abstract Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by perpet-
uated inflammation in multiple joints. To date, there is no cure for RA, and the causal factor for
non-resolving inflammation in RA remains unclear. In this study, we initially observed expression
of EpsteineBarr virus-encoded small RNA1 (EBER1) in the synovial tissue of all five patients who
showed nonresolving RA inflammation. By contrast, EBER1 was detected in the synovial tissue of
only one out of seven patientswith advanced osteoarthritis (OA; p< 0.01, Fisher’s exact test). To
confirm this finding, we conducted a second study on synovial tissue samples taken from 23
patients with nonresolving RA inflammation and 13 patients with OA. All synovial samples from
patients with nonresolving inflammation of RA showed positive expression of EBER1 (23/23,
100%), whereas none of the synovial samples from patients with OA showed expression of EBER1
(0/13, 0%; p< 0.001, by Fisher’s exact test). In vitro, transfection of RA synovial fibroblasts with
EBER1 induced the production of interleukin-6. Taken together, these data strongly suggest that
nonresolving RA inflammation is strongly related to the presence of EBER1, which might be, at
least partially, responsible for synovial fibroblast interleukin-6 production.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung
iversity College of Medicine, Number 123, Ta Pei Road, Niao Sung District, Kaohsiung 83301, Taiwan.
mh.org.tw (C.-J. Chen).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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EBER1 and rheumatoid arthritis 607IntroductionRheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by perpetuated inflammation in multiple
joints, which usually causes deformity and disability in
cases without adequate treatment. At present, only
30e50% of RA patients can achieve complete remission
with the use of various kinds of disease-modifying anti-
rheumatic drugs [1]. In 2010, Nathan and Ding [2] sug-
gested that nonresolving inflammation is a major driver of
many chronic inflammatory diseases, and that RA is a
typical example. They emphasized that to cure, and not
to palliate RA, it may be necessary to synergize current
anti-inflammatory therapy with other therapies that
target the causal factors of the disease. However, the
causal factor of nonresolving inflammation in RA remains
unclear.
We proposed the very straightforward concept that
some persistent stimulation derived from microbial or-
ganisms, such as bacteria or viruses, might play a role in
refractory RA (RA with nonresolving inflammation). In
this study, we investigated the expression of Eps-
teineBarr virus (EBV)-encoded small RNA1 (EBER1) in
refractory RA [3].Table 1 Clinical characteristics of five patients.
Characteristic Patient 1 Patient 2
Gender Female Female Fem
Age (y) 54 38 56
RA disease
duration (y)
>10 6 >10
RF (IU/mL) 130 332 303
Anti-CCP (U/mL) 90.9 d d
Medication
Leflunomide þ þ
Methylprednisolone þ
Hydroxychloroquine þ
Methotrexate þ
Rituximab þ
Associated
condition
Severe left
knee swelling
and disability
Recurrent knee
joint effusion
Refr
w
Depression SLE
Osteoporosis
Acoustic neuroma
Operation Left total knee
arthroplasty
in January 2010
Right knee
arthroscopic
synovectomy
in August 2009
Arth
ri
jo
he
ar
of
ra
jo
20
Anti-CCP Z anti-cyclic citrullinated peptide antibody; RA Z rhe
lupus erythematosus.Materials and methods
Patient details and sample collection
This study was approved by the institutional review board
(No. 98-4059B) at Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung, Taiwan. All RA patients were diagnosed ac-
cording to the American Rheumatism Association 1987
revised criteria for the classification of RA [4] and followed
up at Kaohsiung Chang Gung Memorial Hospital. Although
the general condition of the patients showed some
improvement with disease-modifying antirheumatic drugs,
all patients had suffered from at least one large joint
disability due to persistent joint inflammation despite
medical treatment. Therefore, joint replacement was
performed. All patients gave written informed consent
when they were discharged from the ward, and they were
followed up at the outpatient department.
In the first study, in 2010, synovial tissue samples were
collected from five patients with nonresolving RA inflam-
mation (also termed refractory RA), who were receiving
joint replacement because of severe joint destruction, and
seven patients with osteoarthritis (OA) who were receiving
total knee arthroplasty. The clinical characteristics andPatient 3 Patient 4 Patient 5
ale Male Female
79 77
6 >10
3340 832
d d
þ
actory right
rist swelling
Refractory knee
disability
and swelling
Refractory knee
swelling and
disability
in remission Hypertension Chronic subdural
hemorrhage
Osteoporosis Peptic ulcer
Glaucoma
rodesis of the
ght radiocarpal
int and
miresection
throplasty
the distal
dioulnar
int in September
08
Left-side total
knee arthroplasty
in May 2009
Right-side total knee
arthroplasty in
October 2009
umatoid arthritis; RF Z rheumatoid factor; SLE Z systemic
608 W.-C. Chiu et al.laboratory findings are shown in Table 1. In the second study,
synovial tissue samples were collected from 23 patients with
nonresolving RA inflammation and 13 patients with OA, all of
whom were undergoing total knee arthroplasty.
Histopathology examination
All synovial tissue samples were fixed in 10% buffered
formalin and embedded in paraffin, and 5-mm sections
were stained with hematoxylin and eosin as previously
described [5].
Detection of EBER1 by RNA in situ hybridization
The paraffin-embedded tissue blocks were sectioned in 4-
mm slices. EBER1 was detected by RNA in situ hybridization,
as previously described by Fan and Gulley [6]. To avoid
experimental bias, synovial tissue samples from patients
with refractory RA and OA were processed simultaneously.
In vitro synthesis of EBER1 and measurement of
IL-6 production
Human RA synovial fibroblasts were purchased from Cell
Applications Inc. (San Diego, CA, USA). The pGEMT/EBER1
plasmid was kindly provided by Professor Yu-Sun Chang
from the Graduate Institute of Basic Medical Sciences,
Chang Gung University, Tao-Yuan, Taiwan. EBER1 was pre-
pared by in vitro transcription as previously described [6].
Synovial fibroblasts were seeded in 24-well plates at a
density of 5  104/well. After 24 hours, cells were trans-
fected with 10 mg/mL of purified EBER1 or 10 mg/mL of
poly(I-C) (Sigma-Aldrich, St. Louis, MO, USA) using Lip-
ofectamine 2000 (Invitrogen, Grand Island, NY, USA). At 24
hours, 48 hours, and 72 hours, supernatants were collected
for measurement of interleukin-6 (IL-6) production. Levels
of IL-6 in cell culture supernatants were quantified using
Quantikine human IL-6 kits (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s protocol.
Results
In the initial study, the synovial tissue from all five patients
with nonresolving inflammation of RA exhibited strong
inflammation, including hypertrophy of the synovial lining
with plasma cell and lymphocyte infiltration, as well asTable 2 Expression of EpsteineBarr virus-encoded small
RNA1 (EBER1) in synovial lining cells, plasma cells, endo-
thelial cells, and lymphocytes in five consecutive patients
with refractory rheumatoid arthritis (RA) receiving surgical
intervention.
Age
(y)
Gender Synovial
lining cell
Plasma
cell
Endothelial
cell
Lymphocytes
54 Female þ þ þ þ
38 Female þ þ þ Equivocal
56 Female þ þ þ Equivocal
79 Male þ þ Equivocal e
77 Female þ þ þ eneovascularization. Using RNA in situ hybridization, we
found a strong expression of EBER1 in the synovial speci-
mens from all five patients with refractory RA. EBER1
expression was observed in the synovial lining cells, plasma
cells, endothelial cells, or infiltration lymphocytes (Table 2
and Fig. 1). However, of the synovial tissue samples ob-
tained from patients with OA, only one patient’s sample
was positive for EBER1 (1/7, 14%). There was a statistically
significant difference in EBER1 expression between these
two groups (p < 0.01, Fisher’s exact test).
We expanded the study and assessed EBER1 expression
in synovial samples taken from 23 patients with refractory
RA and 13 patients with OA. Expression of EBER1 was
observed in all samples from patients with refractory RA
(23/23, 100%), with EBER1 expression predominantly
located in the synovial lining cells, plasma cells, and
endothelial cells. However, expression of EBER1 was not
detected in any of the synovial specimens from patients
with OA (0/13, 0%; Table 3). There was a highly statistically
significant difference in EBER1 expression between these
two groups (p < 0.001, Fisher’s exact test).Figure 1. Detection of EpsteineBarr virus-encoded small
RNA1 (EBER1) by RNA in situ hybridization in a patient with
refractory rheumatoid arthritis (RA) compared to a patient
with osteoarthritis (OA). (A) Negative control using a sense
probe for EBER1 (200) in RA. (B) EBER1 detected by RNA in
situ hybridization (200) in a patient with RA.
Table 3 Expression of EpsteineBarr virus-encoded small
RNA1 (EBER1) in synovial tissues of the second study.
EBER1 expressiona RA
(n Z 23)
OA
(n Z 13)
p
Synovial lining cells, 23 (100) 0 (0) <0.001
Plasma cells 23 (100) 0 (0) <0.001
Endothelial cells 23 (100) 0 (0) <0.001
Infiltration lymphocytes 15 (65.2) 0 (0) <0.001
Data are presented as n (%).
a There was a significant difference in EBER1 expression be-
tween rheumatoid arthritis (RA) group and osteoarthritis (OA)
group (p < 0.0001, Fisher’s exact test).
EBER1 and rheumatoid arthritis 609Furthermore, to investigate the effect of EBER1 on
human RA synovial fibroblasts, we tested whether in vitro
synthesized EBER1 could induce the production of IL-6. As
shown in Fig. 2, EBER1-induced IL-6 production by human
RA synovial fibroblasts was detected at 24 hours and
reached a peak at 72 hours, which indicated EBER1-
mediated activation of human RA synovial fibroblasts.
Discussion
EBV has been speculated to be related to RA since 1976,
when Aslpaugh and Tan [7] discovered that patients with
seropositive RA have a high frequency of antibodies to aFigure 2. Production of interleukin (IL)-6 protein by human rh
teineBarr virus-encoded small RNA1 (EBER1) and poly(I-C). Values
*p < 0.05.nuclear antigen present only in EBV-transformed lympho-
cytes. In 1978, Slaughter et al. [8] reported that lympho-
cytes taken from RA patients spontaneously transformed
into cell lines more often and more quickly than lympho-
cytes taken from normal controls. Furthermore, infection
of RA lymphocytes with EBV induced the production of
more IgM rheumatoid factor [8]. However, in early studies,
EBV-DNA was not detected within the synovial tissues of RA
patients. In 1997, Takei et al. [9], using a highly sensitive
technique, were the first to report that EBER1 was observed
in the synovial lining cells in 23.5% (8/34) of chronic RA
patients. In 2000, Takeda et al. [10] detected EBER1 by RNA
in situ hybridization in only five of 32 patients with RA.
However, in contrast to our study, in which the patients
were all positive for rheumatoid factor and refractory
arthritis, the patients in Takeda’s study were heteroge-
neous for RA and were not limited to patients with re-
fractory RA. Here, we report the expression of EBER1 in the
synovial tissue of all the patients in our study with re-
fractory RA, showing that the presence of EBER1 in synovial
tissue is strongly related to nonresolving inflammation in
RA.
However, it is unclear whether EBER1 is the cause of
persistent inflammation in RA. EBER1 is a poly(A)-, non-
coding RNA that is expressed abundantly in all forms of cells
latently infected with EBV. Its biologic function has not
been made clear until 2009, when Iwakiri et al. [11]
discovered that EBER1 induces cell signaling through acti-
vation of Toll-like receptor 3 and induces type I interferoneumatoid arthritis (RA) synovial fibroblasts treated with Eps-
are expressed as the mean and standard error of the mean.
610 W.-C. Chiu et al.and proinflammatory cytokine production in lympho-
blastoid cell lines. Moreover, human monocyte-derived
dendritic cells treated with EBER1 showed mature pheno-
type and antigen presentation capacity [11]. Toll-like re-
ceptor 3 is also expressed in synovial fibroblasts [12],
endothelial cells [13], and plasma cells [14], which suggests
that EBER1 may also be involved in the activation of these
cells. Our current observation of the positive staining of
EBER1 in synovial lining cells, endothelial cells, and plasma
cells seems compatible with this hypothesis. Moreover, we
report the novel observation that EBER1 is capable of
activating primary human RA synovial fibroblasts, resulting
in the induction of IL-6 production (Fig. 2).
Further evidence to support our hypothesis that EBER1 is
associated with refractory RA is provided by a study from
Sweden published in 2010 [15]. Anti-CD20 treatment was
given to RA patients who had been nonresponsive to anti-
TNF-a treatment. Prior to treatment, EBV was identified in
15 (43%) out of the 35 patients. Bone marrow and blood
samples obtained from these 15 EBV-positive patients 3
months after anti-CD20 treatment were EBV-negative.
Moreover, a significantly better anti-CD20 therapy effect
and lower relapse rate were observed in the EBV-positive
patients as opposed to non-EBV patients [15]. This finding
suggests that EBV infection in refractory RA patients plays
an important role in the nonresolving RA inflammation.
In this study, we observed that poly(IC) induced higher IL-
6 production than EBER1 from human RA synovial fibroblasts,
suggesting that non-EBV-derived RNA could also stimulate
synovial fibroblasts to produce IL-6. Indeed, Brentano et al.
[16] reported that RNA release from necrotic synovial fluid
cell from patients with RA activated RA synovial fibroblasts
to release IL-6 in vitro [16]. However, it is unknown whether
RNA can activate synovial fibroblasts in vivo. In the future,
studies to determine whether RNAs other than EBER1 are
present in the synovial fluid and tissues of RA patients are
worth pursuing. Furthermore, it would be interesting to
assess and compare the expression of EBER1 among RA and
non-RA inflammatory arthritis, and determine whether
EBER1 is specific for RA.
In brief, although the initial etiology of RA is still un-
clear, our study suggests that nonresolving inflammation in
RA is strongly associated with the presence of EBER1 in
synovial tissue.
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